204 related articles for article (PubMed ID: 16820916)
1. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
3. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
[TBL] [Abstract][Full Text] [Related]
4. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009
[No Abstract] [Full Text] [Related]
5. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
[TBL] [Abstract][Full Text] [Related]
7. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
[TBL] [Abstract][Full Text] [Related]
8. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 may be effective against peritoneal dissemination in gastric cancer.
Yamagata S; Nakata B; Hirakawa K
Oncol Rep; 2004 Nov; 12(5):973-8. PubMed ID: 15492780
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
10. [TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
Tanaka T; Fujita S; Tanaka N; Ooka M; Okajima S; Tanaka N
Gan To Kagaku Ryoho; 2005 Jun; 32(6):841-5. PubMed ID: 15984528
[TBL] [Abstract][Full Text] [Related]
11. Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
Lim HS; Ryu KW; Lee JH; Kim YW; Ju Choi I; Kim MJ; Park YI; Hwang A; Park SR
J Clin Pharmacol; 2015 Aug; 55(8):926-35. PubMed ID: 25810324
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Liu HY; Ding L; Yu Y; Chu Y; Zhu H
Yao Xue Xue Bao; 2012 Oct; 47(10):1363-9. PubMed ID: 23289150
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer.
Cohen SJ; Leichman CG; Yeslow G; Beard M; Proefrock A; Roedig B; Damle B; Letrent SP; DeCillis AP; Meropol NJ
Clin Cancer Res; 2002 Jul; 8(7):2116-22. PubMed ID: 12114411
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
15. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.
Mori T; Fujiwara Y; Yano M; Tamura S; Yasuda T; Takiguchi S; Monden M
Oncology; 2003; 64(2):176-82. PubMed ID: 12566916
[TBL] [Abstract][Full Text] [Related]
16. [Drug distribution in gastric cancer and adjacent tissues by preoperative intraperitoneal chemotherapy with Co-fluorouracil liposome].
Li Y; Liu BW; DU WL; Song ZC; Zhao Q; Fan LQ; Yang JQ; Li QJ; Wang MX; Jiao ZK; Zhang ZD
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):638-40. PubMed ID: 15634532
[TBL] [Abstract][Full Text] [Related]
17. [A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function].
Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Tanaka J; Oshiro R; Tatsuta M; Masutani S; Fukunaga M; Nakayama T; Takemoto H; Kondo M; Kamigaki S; Kawasaki T
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1748-51. PubMed ID: 16315929
[TBL] [Abstract][Full Text] [Related]
18. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
19. A phase I study evaluating the effect of CDHP as a component of S-1 on the pharmacokinetics of 5-fluorouracil.
Saif MW; Rosen LS; Saito K; Zergebel C; Ravage-Mass L; Mendelson DS
Anticancer Res; 2011 Feb; 31(2):625-32. PubMed ID: 21378348
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of S-1 for gastric cancer patients with positive peritoneal lavage cytology.
Ako E; Ohira M; Yamashita Y; Kubo N; Muguruma K; Yashiro M; Sawada T; Nakata B; Kato Y; Hirakawa K
Hepatogastroenterology; 2008; 55(86-87):1939-42. PubMed ID: 19102427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
